We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Studies Examining the Importance of Smoking After Being Diagnosed With Lung Cancer (LungCast)

This study is currently recruiting participants.
Verified February 2016 by Dr Keir Lewis, Hywel Dda Health Board
ClinicalTrials.gov Identifier:
First Posted: September 1, 2010
Last Update Posted: February 19, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Cardiff and Vale University Health Board
Information provided by (Responsible Party):
Dr Keir Lewis, Hywel Dda Health Board

A large project consisting of:

a) an observational trial where smoking status is recorded on 1400 consecutive people newly diagnosed with lung cancer. Smoking status is biologically validated with exhaled carbon monoxide (eCO) levels every 3 months. Survival, cancer progression and treatment complications will be recorded and compared in smokers, ex-smokers and never smokers.

Lung Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Does Smoking Status After Being Diagnosed With Lung Cancer Influence Outcome? An Observational Cohort Study.

Resource links provided by NLM:

Further study details as provided by Dr Keir Lewis, Hywel Dda Health Board:

Primary Outcome Measures:
  • Median and 2-year survival rates in confirmed smokers versus non- smokers newly diagnosed with lung cancer. [ Time Frame: 24 months ]

Secondary Outcome Measures:
  • Median survival and 2-year survival rates by smoking status for early (Stage I/II NSCLC) versus those with advanced (Stage III/IV) NSCLC. [ Time Frame: 24 months ]
  • Number of treatment complications in smokers versus non-smokers (frequency surgical wound complications, radiotherapy induced pneumonitis and median total radiation (Gy) dose; frequency and duration of neutropenic sepses [ Time Frame: 2 years ]
  • Point prevalence of smoking at 0, 3, 6 12, 24 months [ Time Frame: 2 years ]
  • Comparison of changes in health related quality of life (EQ5D) in smokers versus non-smokers [ Time Frame: 2 years ]
  • Accrual and attendance rates of lung cancer patients attending a hospital smoking cessation service [ Time Frame: 2 years ]
  • Estimate of cost per quality adjusted life year gained by smoking cessation advice in both quit strategies for smokers [ Time Frame: 2 years ]

Estimated Enrollment: 2400
Study Start Date: March 2010
Estimated Study Completion Date: March 2019
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Detailed Description:

Smoking causes around 85% of lung cancer. Continued smoking after diagnosis probably worsens survival and increases treatment complications but prospective well-designed studies are lacking.

This project is an observational cohort study recording outcomes in smokers, never-smokers, and ex-smokers, using exhaled carbon monoxide to validate smoking status when they attend for further lung cancer clinics.

This project is unique, as every patient with a clinical diagnosis of lung cancer will have their smoking status biologically validated by a quick and easy test, and those enrolled in the smoking cessation treatments or not will also complete a generic quality of life questionnaire at regular intervals. These appointments will coincide with other hospital appointments wherever possible, and survival status will reported up to 24 months after enrolment.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with newly diagnosed lung cancer

Inclusion Criteria:

  • clinical diagnosis of lung cancer

Exclusion Criteria:

  • refusal Consent
  • inability to provide exhaled CO
  • active psychiatric illness or substance misuse
  • concurrent malignancies of another type other than non-melanoma skin cancer
  • unable to travel for sessions with smoking cessation counsellor and / or outpatient visits from outset
  • WHO performance status 4
  • Life expectancy less than 6 weeks.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01192256

Contact: Rachel E Roberts, BSc 44 1554756567 ext 3569 r.e.roberts@swansea.ac.uk
Contact: Keir Lewis, MD FRCP +44 1554783133 k.e.lewis@swansea.ac.uk

United Kingdom
Llandough Hospital, Cardiff and Vale University Health Board Recruiting
Cardiff, Wales, United Kingdom
Contact: Diane Parry, FRCP    +44 2920 747747    diane.parry@wales.nhs.uk   
Contact: Tamsin Rees       tamsin.rees@wales.nhs.uk   
Sub-Investigator: Ian Campbell, FRCP         
Sub-Investigator: Tamsin Rees, BSc         
Sub-Investigator: Helen Davies, MRCP         
Hywel Dda Health Board Recruiting
Llanelli, Wales, United Kingdom, SA14 8QF
Contact: Keir E Lewis, MD    +44 1554783133    k.e.lewis@swansea.ac.uk   
Contact: Chris Tattersall, BSc       chris.tattersal@wales.nhs.uk   
Sub-Investigator: Gareth Collier, MRCP         
Principal Investigator: Rachel Roberts, BSc         
Sponsors and Collaborators
Dr Keir Lewis
Cardiff and Vale University Health Board
Principal Investigator: Keir E Lewis, MD Hywel Dda
  More Information

Responsible Party: Dr Keir Lewis, Reader in Medicine and Consultant Chest Physician, Hywel Dda Health Board
ClinicalTrials.gov Identifier: NCT01192256     History of Changes
Other Study ID Numbers: 09/WMW01/28
WS763986 ( Other Grant/Funding Number: GRAND Pfizer )
First Submitted: August 27, 2010
First Posted: September 1, 2010
Last Update Posted: February 19, 2016
Last Verified: February 2016

Keywords provided by Dr Keir Lewis, Hywel Dda Health Board:
quality of life

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases